Hepatocellular Cancer: New Kids on the Block | Zendy

Andreas-Claudius Hoffmann | Zendy; Guido Gerken | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Hepatocellular Cancer: New Kids on the Block

Author(s) -

Andreas-Claudius Hoffmann,

Guido Gerken

Publication year - 2014

Publication title -

gastrointestinal tumors

Language(s) - English

Resource type - Journals

eISSN - 2296-3766

pISSN - 2296-3774

DOI - 10.1159/000380787

Subject(s) - sorafenib , medicine , hepatocellular carcinoma , clinical trial , cancer , cancer research , cabozantinib , oncology

With over 600,000 newly diagnosed hepatocellular cancer (HCC) patients worldwide every year and ongoing clinical research, it is surprising that many of the new molecular entities have not yet resulted in significant prolongation of progression-free or overall survival. Nevertheless, there are a number of promising agents currently under investigation. Given the unique tumor biology and heterogeneous clinical manifestations of HCC, the application of molecular and cellular markers could also benefit patient selection, disease prognosis and trial design.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research